Clinical Trial Update: Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating vemurafenib plus cobimetinib plus PEG-interferon in advanced melanoma with BRAF V600 mutation completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cobimetinib (cobimetinib)
• Peg-interferon (pegylated interferon alfa)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Fondazione Melanoma Onlus | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED